Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction

[1]  B. Pitt,et al.  Reduced Diuretic Dose in Patients Treated With Eplerenone , 2020, Circulation. Heart failure.

[2]  S. Solomon,et al.  Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC Heart Failure Position Paper. , 2020, JACC. Heart failure.

[3]  L. Rohde,et al.  Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. , 2019, European heart journal.

[4]  Akshay S. Desai,et al.  Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF. , 2019, Journal of the American College of Cardiology.

[5]  Akshay S. Desai,et al.  Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial , 2019, European journal of heart failure.

[6]  Nicola Orsini,et al.  Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. , 2018, JACC. Heart failure.

[7]  J. Nanas,et al.  Loop diuretics for chronic heart failure: a foe in disguise of a friend? , 2018, European heart journal. Cardiovascular pharmacotherapy.

[8]  J. Cleland,et al.  Cardiac Dysfunction, Congestion and Loop Diuretics: their Relationship to Prognosis in Heart Failure , 2016, Cardiovascular Drugs and Therapy.

[9]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[10]  J. McMurray,et al.  Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction , 2016, European journal of heart failure.

[11]  Volkmar Falk,et al.  2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.

[12]  J. McMurray,et al.  Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. , 2015, European heart journal.

[13]  V. Hasselblad,et al.  Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND‐HF , 2014, European journal of heart failure.

[14]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[15]  Akshay S. Desai,et al.  Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction , 2014, Circulation. Heart failure.

[16]  M. Kearney,et al.  Prospective development and validation of a model to predict heart failure hospitalisation , 2014, Heart.

[17]  L. Tavazzi,et al.  Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis , 2013, International journal of clinical practice.

[18]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[19]  R. McKelvie,et al.  Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial , 2011, Circulation. Heart failure.

[20]  C. Brensinger,et al.  Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. , 2011, Journal of the American College of Cardiology.

[21]  J. P. Araújo,et al.  Prognostic Implications of Diuretic Dose in Chronic Heart Failure , 2011, Journal of cardiovascular pharmacology and therapeutics.

[22]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[23]  J. McMurray,et al.  Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF) , 2010, European journal of heart failure.

[24]  J. Daubert,et al.  Cardiac resynchronization therapy: are modern myths preventing appropriate use? , 2009, Journal of the American College of Cardiology.

[25]  Akshay S. Desai,et al.  The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. , 2008, Journal of cardiac failure.

[26]  Karl Swedberg,et al.  Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure , 2007, Circulation.

[27]  G. Fonarow,et al.  Relation of loop diuretic dose to mortality in advanced heart failure. , 2006, The American journal of cardiology.

[28]  M. Gheorghiade,et al.  Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. , 2006, European heart journal.

[29]  J. Rouleau,et al.  Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial , 2004, Circulation.

[30]  R. Wenzel.  Diuretics in heart failure. , 1986, Lancet.